News

Alzheimer's research to watch for at AAN


 

Alzheimer's disease sessions and lectures at this year's American Academy of Neurology annual meeting continue the theme of early detection of symptoms and intervention for modifiable risk factors that have become ever more relevant to ongoing research and treatment efforts.

  • Genetics, imaging, and other biomarkers allow us to identify those individuals at the greatest risk, while prevention trials and disease modifying agents have gone from dream to reality. Among the best sessions for these should be Tuesday's Hot Topics plenary session lecture by Alison Goate, D.Phil., titled "Rare and Common Genetic Risk Factors for Alzheimer’s Disease," and the oral abstract session "Amyloid Imaging in the Prediction of and Diagnosis of Alzheimer's Disease," both on March 19. There’s also the Integrated Neuroscience Session, "Alzheimer's Biomarkers in Clinical Practice," on March 18.
  • Trials of monoclonal antibodies, such as solanezumab and bapineuzumab, continue to show enough of an effect to keep our interest on amyloid-modifying therapies, but clinical outcomes remain disappointing and again echo the theme that earlier intervention may be needed. These can be found in the March 20 oral abstract session "Aging and Dementia: Epidemiology and Clinical Science," and the March 22 Clinical Trials plenary presentation by Dr. Ann Hake on solanezumab.
  • New studies continue to provide evidence in support of "mom's recipe for good health,", i.e., sleep, exercise, and a good diet, and we can only hope that preventing or delaying dementia will add further impetus to the public to comply with these habits.
  • At the Hot Topics plenary, Dr. John Trojanowski’s study on spreading tau fibrils in a transgenic mouse model of Alzheimer’s-like tauopathy should be absorbing. We have suspected this sort of tau fibril transmission in amyotrophic lateral sclerosis, of course (their presence in upper and lower motor neurons hardly seems like a coincidence), but it has been more difficult to prove in anatomically more complex areas like the hippocampus. His study contributes importantly to other research suggesting that a degenerative disease starts in a specific area and spreads from there (just as the stages of pathology have always implied).

Recommended Reading

Study identifies predictors of cognitive impairment in schizophrenia
MDedge Neurology
Vascular lesions hurt cognition more than amyloid
MDedge Neurology
New Alzheimer's drug yields modest memory improvements
MDedge Neurology
Alzheimer's Assessment Scale May Not Be Accurate Enough
MDedge Neurology
Medicare Needs More Data Before Covering Amyloid Scans
MDedge Neurology
Cardiac Disease May Double Women's Risk of Cognitive Impairment
MDedge Neurology
Folic Acid Supplements May Be Associated With Lower Autism Risk
MDedge Neurology
Vascular Lesions May Impair Cognition More Than Amyloid Deposition
MDedge Neurology
Report Outlines Amyloid PET Imaging Criteria for Alzheimer's Disease
MDedge Neurology
New and Noteworthy Information—March
MDedge Neurology